Ioflupane (123i) Rotop (Ioflupane (123i))

After intravenous injection, the iodine‑123‑labeled Ioflupane molecule binds with high affinity to presynaptic dopamine transporters (DAT) on dopaminergic neurons. The bound tracer emits gamma photons that are captured by a SPECT camera, producing a quantitative map of DAT density that reflects neuronal health and allows detection of dopaminergic loss.

The administered activity of Ioflupane (123i) Rotop is determined by the prescribing physician or nuclear medicine specialist based on patient weight, age, and the specific imaging protocol. Dosage is individualized and should follow local regulatory guidelines and the product’s prescribing information.

Safety data in pregnant or lactating women are limited, and the radiopharmaceutical delivers ionising radiation to the fetus or infant. Use is generally avoided unless the diagnostic benefit outweighs potential risks, and appropriate radiation protection measures are applied. Breastfeeding should be discontinued for a period advised by the treating physician.

To request Ioflupane (123i) Rotop, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details—including cold‑chain handling if needed—and necessary import documentation.

Ioflupane (123i) is an iodine‑123‑labeled tracer, offering high‑resolution SPECT images and a favorable radiation dose compared with older agents such as ^99mTc‑based compounds. Its strong DAT affinity provides reliable quantification, while alternatives like ^18F‑FP‑CIT are PET tracers requiring different imaging infrastructure. Choice depends on available equipment, regulatory status, and clinical preference.

Ioflupane (123i) Rotop must be stored refrigerated at 2‑8 °C, protected from light, and kept in its original sealed vial. Do not freeze or shake the solution, as physical stress can affect radiochemical stability. Prior to use, allow the vial to reach room temperature if required by the imaging protocol.

The product is supplied as a sterile solution for injection. It is administered intravenously by a qualified healthcare professional, typically as a single bolus injection. After injection, a waiting period of about 3‑6 hours is observed before SPECT imaging to allow optimal brain uptake and clearance of background activity.

The most significant concerns are allergic reactions, including anaphylaxis, and radiation‑related effects, particularly in repeated exposures. Severe hypotension may occur shortly after injection. Patients should be monitored for immediate hypersensitivity signs, and cumulative radiation dose should be considered in the context of overall diagnostic imaging history.

Contra‑indications include patients with known hypersensitivity to iodine‑123‑labeled compounds or any component of the formulation, and individuals for whom the radiation exposure is deemed unjustifiable, such as pregnant women without a compelling clinical indication. Caution is also advised in patients with severe renal impairment or those taking strong DAT‑blocking medications.